Figure 1.
Survival curves of 385 patients MCL experiencing late POD. (A) PFS from time of second-line therapy (PFS-2; median, 33 months). (B) Overall survival from time of second-line therapy (OS-2; median, 60 months). Median follow-up for survivors from time of second-line therapy was 53 months (range, 1-144).

Survival curves of 385 patients MCL experiencing late POD. (A) PFS from time of second-line therapy (PFS-2; median, 33 months). (B) Overall survival from time of second-line therapy (OS-2; median, 60 months). Median follow-up for survivors from time of second-line therapy was 53 months (range, 1-144).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal